文献速递免疫规划传染病防控与疫情报告

随机、盲法、对照III期临床试验:评估冻干人用狂犬病疫苗(Vero细胞)4剂方案(2-1-1)在10-60岁人群中的免疫原性与安全性

Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.
PubMed 文献 · Vaccine · 2024-06-27

该随机盲法对照III期试验纳入1800名10-60岁受试者,分4剂试验组、4剂对照组和5剂对照组,评估冻干人用狂犬病疫苗(Vero细胞)4剂方案(2-1-1)的免疫原性与安全性。结果显示三组首剂后14天和全程后14天血清阳转率均为100%,4剂试验组抗体GMC高于5剂对照组但略低于4剂对照组;首剂后7天两个4剂方案组血清阳转率和抗体GMC均高于5剂方案组;4剂试验组不良事件总体发生率与5剂对照组无显著差异,但显著低于4剂对照组。

要点

  • 三组首剂后14天和全程后14天血清阳转率均为100%
  • 4剂试验组抗体GMC高于5剂对照组但略低于4剂对照组
  • 首剂后7天两个4剂方案组免疫原性优于5剂方案组

核心结论

  • 4剂试验组疫苗免疫原性与4剂对照组疫苗相当且优于5剂对照组疫苗。
  • 4剂试验组疫苗安全性与5剂对照组疫苗相当且优于4剂对照组疫苗。

研究设计与样本

  • 随机、盲法、对照III期临床试验,共纳入1800名10-60岁受试者。
  • 受试者分为4剂试验组、4剂对照组和5剂对照组三组。
  • 采用快速荧光灶抑制试验检测狂犬病病毒中和抗体以评估免疫原性。
  • 统计分析了不良事件和严重不良事件的发生率。

主要发现

  • 三组首剂后14天和全程接种后14天血清阳转率均为100%。
  • 4剂试验组抗体GMC高于5剂对照组,但略低于4剂对照组。
  • 首剂后7天,两个4剂方案组血清阳转率和抗体GMC均高于5剂方案组。
  • 4剂试验组不良事件总体发生率与5剂对照组无显著差异,但显著低于4剂对照组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study is to demonstrate that the freeze-dried human rabies vaccine (Vero cell), administered in a four-dose schedule (2-1-1) to the 10-60 years old population, has immunogenicity that is not inferior to the approved five-dose schedule and similar vaccines with a four-dose schedule, and to evaluate its safety. METHOD: A total of 1800 individuals were enrolled and divided into three groups: four-dose test group, four-dose control group, and five-dose control group. The rabies virus neutralizing antibodies were measured using the Rapid Fluorescent Focus Inhibition Test to assess immunogenicity, and the incidence of adverse events and serious adverse events were statistically analyzed. RESULTS: The seroconversion rates 14 days after the first dose and 14 days after the complete course of vaccination were 100% in all three groups. The antibody GMC of the four-dose test group was higher than that of the five-dose control group, but slightly lower than the four-dose control group. Seven days after the first dose, both four-dose regimen groups showed higher seroconversion rates and antibody GMCs compared to the five-dose regimen group, proving that the immunogenic effect of the four-dose regimen seven days post-first vaccination is superior to the five-dose regimen. The overall incidence of adverse events showed no significant difference between the four-dose test group and the five-dose control group, but was significantly lower in the four-dose test group compared to the four-dose control group. CONCLUSION: The vaccine in the four-dose test group is equivalent in immunogenic effect to the four-dose control group vaccine and superior to the five-dose control group vaccine; the safety of the vaccine in the four-dose test group is equivalent to the five-dose control group vaccine and superior to the four-dose control group vaccine. CLINICALTRIALS: gov number: NCT05549908.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jin F, Zhu L, Wang Y, et al. Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic. Vaccine. 2024. PMID: 38937182. doi:10.1016/j.vaccine.2024.06.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。